Whole genome sequencing in newborn screening?  A Statement on the continued importance of targeted approaches  in newborn screening programmes by Knoppers, Bartha Maria et al.
Whole genome sequencing 
in newborn screening? 
B.M. Knoppers1, H.C. Howard2, M. Cornel3, E. Wright Clayton4, K. Sénécal1, P. Borry5
A Statement on the continued importance of targeted approaches
 in newborn screening programs.
P231
1 Centre of  Genomics and Policy,  McGill University, Canada. 
2 Centre for Research Ethics & Bioethics, Uppsala University, Sweden.
3 Department of Clinical Genetics and EMGO Institute for Health and Care 
Research, VU University Medical Center, The Netherlands.
4 Center for Biomedical Ethics and Society, Vanderbilt University, USA.
5 Department of Public Health and Primary Care, University of Leuven, 
Belgium.
Background
Objectives
Unsolicited Findings: An approach using a targeted sequencing or targeted analysis will likely limit the number of unsolicited findings. However, 
unsolicited findings indicative of serious health problems for the child should still be reported to parents where treatment or prevention is available during 
childhood. Moreover, as carrier status information may be relevant to parents for reproductive choices, they could be offered this information. Parents may 
also be offered information regarding unsolicited findings that are severe and clinically actionable relevant to their own health.
Costs: The infrastructure and human resource costs to ensure monitoring, appropriate education, counseling, interventions and storage must be assessed. 
Appropriate studies should be undertaken to obtain a realistic picture of all costs involved as part of NBS in a public health programme, including subsequent 
diagnostic costs as well as the costs of not implementing genome sequencing.
Purpose: The primary objective of genome sequencing in NBS should be the identification of gene variants conferring a high risk of preventable or 
treatable conditions, for which treatment has to start in the newborn period or in early childhood. This includes the selection of mutations that are clearly 
pathogenic, are known to have high penetrance and for which effective and accepted preventive therapeutic interventions are available. 
At this time, we recommend a targeted sequencing or targeted analysis approach. 
Evidence: A robust evidence base is a prerequisite for responsible and effective NBS. This evidence base requires: the understanding of the presence of 
mutations in certain populations; the sensitivity and specificity of tests; the identification of treatment pathways or preventive action; the calculation of 
immediate and downstream costs; the assessment of lives saved and the potential impact on families; and finally, the determination of public acceptability.
Engagement: The perception of the harm and benefits of screening is very different among different stakeholders. For this reason, it is important to 
have an open dialogue about the expected medical and social benefits with all stakeholders, including patients and their representatives and the general 
public. Moreover, governments should engage with key opinion leaders to establish sound policy to guide any integration of genome sequencing into NBS. 
This would enable a population health approach to be followed, key frameworks to be developed, support decision making in relation to the conditions for 
which screening could be offered and would support a consistent approach between jurisdictions within a region.
Informing parents: Even if only targeted genome sequencing is adopted, new NBS models of informing parents will have to be developed. They should 
provide the necessary information but also maximize participation rates as the main focus of NBS should always be the identification and treatment of the 
asymptomatic, at-risk newborn. These should also include information about potential storage and research uses of the samples and data.
Educating professionals and the public: Attention should be paid to the particular education and training needs of the health care professionals 
involved in NBS screening. This includes the development of public education programmes to increase public understanding of both genomics and newborn 
screening, their benefits and limitations.
Future uses beyond NBS: Storing the whole genome sequence or large amounts of sequence information of newborns for health care purposes is 
premature at this time. Policy makers need to consider uses to improve public health and research as well as its potential to identify individuals and their 
relatives.
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Method
Yet the routine nature of NBS with its implied consent and public health rationale as well as the vulnerability of the 
newborn population could make such problems unsuitable for a WGS-based approach.
The aim of this project was to develop consensus recommendations on the possible introduction of WGS into 
NBS programs. The recommendations are not meant as an encouragement to use new sequencing tools or genome 
sequencing approaches in NBS programs, but rather they offer a list of areas that must be carefully addressed should 
stakeholders consider using said technologies and approaches in NBS programs.
To formulate the Recommendations, we: 
reviewed both the normative texts guiding newborn screening programs and the relevant literature addressing 
the issues raised by WGS  in NBS to identify both existing and emerging guidance; 
developed a background paper and draft recommendations;
validated the recommendations through a series of consultations with:
members of the Professional and Public Policy Committee of the European Society of Human Genetics;
Human Genome Organisation Committee on Ethics, Law and Society;
P3G International Paediatric Platform.
Next generation sequencing technologies, including whole genome sequencing (WGS), are powerful technologies can sequence the entire genome of a person. This can 
be used at any stage of life, including at birth. The rapid development of WGS has led some to predict that the use of this technology will change the current practice of 
medicine and public health by enabling more accurate, sophisticated and cost-effective genetic testing1. Some even believe that “the earliest applications of WGS will be 
restricted to settings in which genetic testing is already a routine part of clinical or public health practice, such as state newborn screening (NBS) programs.”2 
Conclusion
Before such tools and approaches are introduced into newborn screening 
programs (NBS), the goals and values of these programs should be explicitly 
articulated. The responsible use of WGS within a public health program such 
as NBS should not be technology driven, but rather be adopted on the basis 
of its public health potential. 
The primary justification for performing WGS within the context of newborn 
screening should be the health interests of the child.
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